The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and activity of the multikinase inhibitor sorafenib in heavily pretreated patients with refractory/relapsed malignant lymphomas: Final results of a phase II study.
A. Guidetti
No relevant relationships to disclose
C. Carlo-Stella
No relevant relationships to disclose
S. Viviani
No relevant relationships to disclose
L. Devizzi
No relevant relationships to disclose
S. Locatelli
No relevant relationships to disclose
P. Matteucci
No relevant relationships to disclose
A. Marchianò
No relevant relationships to disclose
R. Lanocita
No relevant relationships to disclose
M. Magni
No relevant relationships to disclose
A. Dodero
No relevant relationships to disclose
C. Tarella
No relevant relationships to disclose
M. A. Di Nicola
No relevant relationships to disclose
P. Corradini
No relevant relationships to disclose
A. M. Gianni
No relevant relationships to disclose